(Q37979858)

26 August 2017

title

The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury (English)

1 reference

26 August 2017

David E Amacher

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

31 January 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

26 August 2017

published in

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

335-347

1 reference

Acute Liver Failure in the United States

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Idiosyncratic drug-induced liver injury: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Case definition and phenotype standardization in drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Incidence of drug-induced hepatic injuries: a French population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Drug-induced liver injury: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Hepatic safety of antibiotics used in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

The disposition of clavulanic acid in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Risk factors for idiosyncratic drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Idiosyncratic drug reactions: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Various forms of chemically induced liver injury and their detection by diagnostic procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Mechanisms of immune-mediated liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Involvement of the immune system in idiosyncratic drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Review article: drug-induced liver injury in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Drug-induced liver injury in humans: the case of ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Current concepts of mechanisms in drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Drug metabolite profiling and elucidation of drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Bioactivation and hepatotoxicity of nitroaromatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Deleterious effects of reactive metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Role of metabolism in drug-induced idiosyncratic hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Glucuronidation and the UDP-glucuronosyltransferases in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

GSTT1 and GSTM1 null genotypes may facilitate hepatitis C virus infection becoming chronic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Aromatic antiepileptic drugs and mitochondrial toxicity: effects on mitochondria isolated from rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Idiosyncratic NSAID drug induced oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

The metabolism of diclofenac--enzymology and toxicology perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Unaltered hepatic oxidative phosphorylation and mitochondrial permeability transition in wistar rats treated with nimesulide: Relevance for nimesulide toxicity characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Drug-induced liver injury: is it somehow foreseeable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Genetically determined differences in drug metabolism as a risk factor in drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Genetic predictors of interindividual variability in hepatic CYP3A4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Prediction of severe adverse drug reactions using pharmacogenetic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Drug-induced liver injury: past, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

MRP2 haplotypes confer differential susceptibility to toxic liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Pharmacogenomics in drug induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

In vitro cytotoxicity assay to evaluate the toxicity of an electrophilic reactive metabolite using glutathione-depleted rat primary cultured hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.658041

10.1517/17425255.2012.658041

21 January 2018

Identifiers

DOI

1 reference

release_p5wkysmwvjffhdmwy6hknnhyry

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p5wkysmwvjffhdmwy6hknnhyry

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference